Strand
Strand Life Sciences Completes $13M Financing Round
Private equity firm Quadria Capital led the investment round and was joined by HealthQuad Fund and Heritas Venture Fund.
Venaxis, Strand Terminate Merger Plans
The two companies, who announced the merger in January, said they could not complete the terms of their deal in a timely enough manner.
UPDATE: Strand's India Laboratory Receives CAP, NABL Accreditations
The Strand Center for Genomics and Personalized Medicine lab is now accredited in India to perform three of Strand's most popular tests.
Venaxis Merges With Strand Life Sciences
Once the deal is fully concluded, Strand's shareholders will own approximately 68 percent of the new company, while Venaxis shareholders will own 32 percent.
Strand provides a standard of care report that includes a handful of genes and IHC markers within eight days, and the full 152-gene report seven to 12 days later.